Need for vaccination against COVID-19 C91 C92
Conditions
Interventions
Group 1: Vaccination against SARSD-CoV-2 according to approval Status
Evaluation of celllular and humaral immunity after vaccination (after first vaccination, 2 weeks and 6 moinths after seciond vaccination)
Sponsors
Pädiatrische Hämatologie und OnkologieKlinik für Kinder- und JugendmedizinJohann Wolfgang Goethe Universität
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: Patients treated for malignoima (both during intensive chemotherapy and in maintenance therapy) up to 3 months after cessation of chemotherapy - Age 16-18 years (youngert once the vaccine will be approved for this age Group) - No contraindication for SARS-CoV-2 vaccination - Written informed consent Patient and caregiver
Exclusion criteria
Exclusion criteria: - known inborn immunodeficiency - Prior infection with SARS-CoV-2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoints Specific antibodies against the spike-Protein and/or nucleocapsid of SARS-CoV-2 Neutralisation test (neutralising antibodies) Specific T cells and specific Memory B cells against SARS-CoV-2 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint Infection or disease with SARS-CoV-2, defined as positive PCR test during study period | — |
Countries
Germany
Contacts
Public ContactThomas Lehrnbecher
Klinik für Kinder und JugendmedizinPädiatrische Hämatologie und Onkologie
Outcome results
None listed